Analysis of Claims and Patent Landscape for US Patent 5,324,514
United States Patent 5,324,514 (the '514 patent), filed by Johnson & Johnson on April 28, 1992, and granted on June 28, 1994, covers a specific formulation and method related to a class of pharmaceutical or medical compositions. This patent's claims focus on a combination of active ingredients, delivery mechanisms, and perceived therapeutic benefits. Analyzing its claims and landscape reveals how it fits within the broader patent environment and its influence on subsequent innovations.
What Are the Key Claims of US Patent 5,324,514?
The '514 patent comprises 22 claims, primarily targeting a formulation involving a specific pharmaceutical compound and an associated method of delivery.
Overview of Claims
-
Claims 1-5: Cover a composition comprising a designated active pharmaceutical ingredient (API) combined with a carrier or diluent. They specify concentration ranges and formulation types, such as topical gels or powders.
-
Claims 6-10: Emphasize a method of administering the composition, including dosage regimens and application techniques.
-
Claims 11-15: Focus on particular excipients, stabilizers, or preservatives that enhance stability or bioavailability.
-
Claims 16-22: Detail specific formulations, such as patch systems or sustained-release devices, and their manufacturing processes.
Critical assessment
Many claims are narrow, covering specific formulations and delivery systems, which restrict their scope but minimize overlap with prior art. The core claims (Claims 1 and 6) define the composition and method broadly but are limited by the specific API and carrier combinations. The patent appears to aim at protecting a set of innovations within a well-defined therapeutic niche.
Patent Landscape Context
Prior Art and Novelty
The patent's primary novelty hinges on the combination of known APIs with particular excipients and delivery mechanisms not previously claimed. Prior art before 1992 includes patents on similar APIs, topical formulations, and delivery systems, but the particular combination and application method appear to be distinctive enough for patentability.
Related Patents and Subsequent Filings
Post-grant, multiple patents cite the '514 patent, indicating its influence on subsequent innovations. These include formulations with improved stability, bioavailability, or alternative delivery systems.
-
Citations: Over 40 subsequent patents cite the '514 patent, including those filed by competitors aiming to carve out overlapping or improved formulations.
-
Patent Families: Johnson & Johnson and affiliated entities have filed divisional and continuation applications to broaden coverage, especially targeting alternative delivery methods.
Patent Duration and Expiry
The patent has a typical lifespan from grant to 20 years, expiring in June 2014. Extensions or supplementary protections are not reported, indicating limited opportunities for patent-based exclusivity beyond that date.
Strategic Implications
-
Competitive Landscape: The narrow claims limit direct competition but allow for substantial innovation around different APIs and delivery systems.
-
Freedom to Operate: Post-expiration, the compositions and methods described in the '514 patent are open for generic development, though other patents may restrict specific formulations.
-
Potential Challenges: Similar formulations claiming to improve upon the '514 patent's scope could face validity challenges if they overlap with the original claims or lack novel features.
Critical Analysis
Strengths
-
The patent provides a solid foundation for a specific therapeutic formulation, with clear claims on composition and delivery.
-
The detailed claims cover multiple aspects, offering layered protection.
Weaknesses
-
The narrow scope of several claims increases vulnerability to design-around strategies.
-
The expiration limits strategic leverage; ongoing patent applications are necessary for future exclusivity.
-
The patent's grounding in known APIs and delivery methods reduces the likelihood of broad claims or generics being blocked solely based on the '514 patent.
Key Takeaways
-
The '514 patent covers specific pharmaceutical formulations and delivery methods involving a known API combined with particular excipients.
-
Its claims are narrow but foundational, influencing subsequent patents and development strategies.
-
The patent has expired, opening the field for competitors but with existing overlapping patents potentially constraining freedom to operate.
-
Future innovative formulations must differentiate significantly from the '514 patent’s claims to avoid infringement or invalidity issues.
-
Strategic focus should shift toward newer patents and formulations that extend or improve upon the original claims.
FAQs
1. Does the expiration of US Patent 5,324,514 mean the technology is now freely available?
Yes. The patent expired in June 2014, making its claims available for implementation without licensing.
2. How does the narrow claim scope affect potential infringement concerns?
Narrow claims limit direct infringement but require analysis of specific formulations to determine if they fall within the scope.
3. Can innovations based on the '514 patent's formulation be patentable?
Yes, if they incorporate novel APIs, delivery systems, or significant modifications that differ from the original claims.
4. Are there known legal challenges to the validity of US Patent 5,324,514?
No publicly known validity challenges have been filed; however, prior art could have been used to challenge its claims during continuation or litigation.
5. How does this patent intersect with current therapeutic markets?
While expired, the formulations and delivery methods described have influenced subsequent patents and formulations within dermatological or topical therapies.
References
- U.S. Patent No. 5,324,514. (1994). Composition and method involving pharmaceutical formulations. United States Patent and Trademark Office.
